Loading
A phase 1/2 trial of tislelizumab in colorectal cancer, run by Fudan University, not yet recruiting.
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer is a phase 1/2, interventional study registered as NCT07025850 by Fudan University, with a registry enrolment figure of 20 participants, started 2025-08-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: Digoxin; Fuquinitinib; Tislelizumab. Conditions listed: Colorectal Carcinoma. Primary outcome: objective response rate (ORR). Sites: China. No results are recorded here; the registry entry is the source.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.